This validation aimed to verify that the selected transcripts (DLG5, CD177, SH2D1B, NQO2, and KRT73) could serve as robust circulating biomarkers capable of distinguishing CRC patients from healthy individuals in a real-world clinical setting. This evidence concerns the gene SH2D1B and colorectal carcinoma.